预防心脏手术相关急性肾损伤:非药物干预的系统评价与Meta分析
该系统评价与Meta分析检索了2004年1月1日至2023年7月1日的PubMed、Embase、Central和临床试验注册库,纳入86项随机对照试验(25,855例患者),评估10种非药物干预对降低心脏手术相关急性肾损伤(CSA-AKI)发生率的效果。主要终点为CSA-AKI发生率。结果显示,目标导向灌注(RR 0.55,95%CI 0.40-0.76)和远程缺血预处理(RR 0.86,95%CI 0.78-0.95)与CSA-AKI发生率显著降低相关,证据质量中等;搏动性血流与降低CSA-AKI相关但证据质量极低(RR 0.69,95%CI 0.48-0.99);限制性输血策略(RR 1.02,95%CI 0.92-1.12)和严格血糖控制(RR 0.86,95%CI 0.55-1.35)无效果,证据质量高。无干预具有高质量证据支持降低CSA-AKI。
要点
- 目标导向灌注与CSA-AKI发生率降低相关(RR 0.55,95%CI 0.40-0.76;I²=0%;Phet=0.44),证据质量中等。
- 远程缺血预处理与CSA-AKI发生率降低相关(RR 0.86,95%CI 0.78-0.95;I²=23%;Phet=0.07),证据质量中等。
- 搏动性血流与CSA-AKI发生率降低相关(RR 0.69,95%CI 0.48-0.99;I²=53%;Phet<0.01),证据质量极低。
- 限制性输血策略无效果(RR 1.02,95%CI 0.92-1.12;Phet=0.67;I²=3%),证据质量高。
- 严格血糖控制无效果(RR 0.86,95%CI 0.55-1.35;Phet=0.25;I²=26%),证据质量高。
适用人群与场景
- 纳入所有评估非药物干预降低CSA-AKI发生率的随机对照试验,不限语言;排除心脏移植或涉及儿科人群的随机对照试验。
诊断标准与关键阈值
- 主要结局变量为CSA-AKI。
研究设计与关键结果
- 系统评价与Meta分析共纳入86项随机对照试验(25,855例患者),评估10种非药物干预对降低CSA-AKI发生率的效果。
- 目标导向灌注与CSA-AKI发生率显著降低相关(RR 0.55,95%CI 0.40-0.76;I²=0%;Phet=0.44),证据质量中等。
- 远程缺血预处理与CSA-AKI发生率显著降低相关(RR 0.86,95%CI 0.78-0.95;I²=23%;Phet=0.07),证据质量中等。
- 体外循环期间搏动性血流与CSA-AKI发生率显著降低相关(RR 0.69,95%CI 0.48-0.99;I²=53%;Phet<0.01),证据质量极低。
- 限制性输血策略无效果(RR 1.02,95%CI 0.92-1.12;Phet=0.67;I²=3%),证据质量高。
- 严格血糖控制无效果(RR 0.86,95%CI 0.55-1.35;Phet=0.25;I²=26%),证据质量高。
- 无干预具有高质量证据支持降低CSA-AKI。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机对照试验;采用GRADE评估证据质量。
- 目标导向灌注和远程缺血预处理降低CSA-AKI的证据质量中等;搏动性血流的证据质量极低;限制性输血策略和严格血糖控制缺乏效果的证据质量高。
- 无干预具有高质量证据支持降低CSA-AKI。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,目标导向灌注和远程缺血预处理可能降低CSA-AKI发生率,证据质量中等。
- 限制性输血策略和严格血糖控制缺乏降低CSA-AKI的效果,证据质量高。
- 无干预具有高质量证据支持降低CSA-AKI,原文未据此给出其他推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiac surgery-associated acute kidney injury (CSA-AKI) is frequent. While two network meta-analyses assessed the impact of pharmacological interventions to prevent CSA-AKI, none focused on non-pharmacological interventions. We aim to assess the effectiveness of non-pharmacological interventions to reduce the incidence of CSA-AKI.
METHODS: We searched PubMed, Embase, Central and clinical trial registries from January 1, 2004 (first consensus definition of AKI) to July 1, 2023. Additionally, we conducted manual screening of abstracts of major anesthesia and intensive care conferences over the last 5 years and reference lists of relevant studies. We selected all randomized controlled trials (RCTs) assessing a non-pharmacological intervention to reduce the incidence of CSA-AKI, without language restriction. We excluded RCTs of heart transplantation or involving a pediatric population. The primary outcome variable was CSA-AKI. Two reviewers independently identified trials, extracted data and assessed risk of bias. Random-effects meta-analyses were conducted to calculate risk ratios (RRs) with 95% confidence intervals (CIs). We used the Grading of Recommendations Assessment, Development, and Evaluation to assess the quality of evidence.
RESULTS: We included 86 trials (25,855 patients) evaluating 10 non-pharmacological interventions to reduce the incidence of CSA-AKI. No intervention had high-quality evidence to reduce CSA-AKI. Two interventions were associated with a significant reduction in CSA-AKI incidence, with moderate quality of evidence: goal-directed perfusion (RR, 0.55 [95% CI 0.40-0.76], I2 = 0%; Phet = 0.44) and remote ischemic preconditioning (RR, 0.86 [0.78-0.95]; I2 = 23%; Phet = 0.07). Pulsatile flow during cardiopulmonary bypass was associated with a significant reduction in CSA-AKI incidence but with very low quality of evidence (RR = 0.69 [0.48; 0.99]; I2 = 53%; Phet < 0.01). We found high quality of evidence for lack of effect of restrictive transfusion strategy (RR, 1.02 [95% CI 0.92; 1.12; Phet = 0.67; I2 = 3%) and tight glycemic control (RR, 0.86 [95% CI 0.55; 1.35]; Phet = 0.25; I2 = 26%).
CONCLUSIONS: Two non-pharmacological interventions are likely to reduce CSA-AKI incidence, with moderate quality of evidence: goal-directed perfusion and remote ischemic preconditioning.
参考来源
- Hariri G, Collet L, Duarte L, et al. Prevention of cardiac surgery-associated acute kidney injury: a systematic review and meta-analysis of non-pharmacological interventions. Crit Care. 2023. PMID: 37700297. doi:10.1186/s13054-023-04640-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。